Nova Eye Medical (EYE) Discussion, page-2049

If 2RT is a success then any position purchased now would be a retirement fund lol. But for iTrack Advance alone that seems fairly reasonable. $5/sh is only a $2.6 billion market cap which would be very realistic (perhaps quite conservative) if MIGS does indeed become the gold standard of treatment in a market currently valued over $6 billion (and likely much bigger in the future). Probably looking quite a few years out though but I definitely do see MIGS becoming the gold standard. A first line approach to glaucoma so as to avoid decades of many expensive and inconvenient drops that often have quite negative side effects.